Assessment of the tolerability profile of an ophthalmic solution of 5% glycyrrhizin and copolymer PEG/PPG on healthy volunteers and evaluation of its efficacy in the treatment of moderate to severe blepharitis

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1403-1410

  Mencucci, Rita ^a   Favuzza, Eleonora ^a   Menchini, Ugo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Blepharitis; Glycyrrhizin; HMGB1

Indexed keywords

COPOLYMER; CORTICOSTEROID; GLYCYRRHIZIC ACID; MACROGOL; POLY(PROPYLENE GLYCOL); UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEPHARITIS; CHRONIC BLEPHARITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SCREENING; DRUG TOLERABILITY; EPIPHORA; EYE BURNING; EYE DISCOMFORT; EYE PHOTOGRAPHY; EYE SWELLING; EYELID DISEASE; EYELID ERYTHEMA; EYELID HYGIENE; EYELID MARGIN ULCERATION; EYELID MARMARGIN ULCERATION; EYELID SWELLING; FEMALE; HUMAN; HYGIENE; MALE; OPEN STUDY; PATIENT COMPLIANCE; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM; VISUAL SYSTEM EXAMINATION; VOLUNTEER;

EID: 84880091794     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S47657     Document Type: Article

References (20)

1. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Blepharitis PPP - Limited Revision - 2011 [webpage on the Internet]. San Francisco: American Academy of Ophthalmology; 2011. Available from: http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=500cd9ca-173c-4c31-b6ea-a258e3549474. Accessed April 25, 2013.
2. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008;43(2):170-179.
3. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1(3):107-126.
4. Cavone L, Muzzi M, Mencucci R, et al. 18b-glycyrrhetic acid inhibits immune activation triggered by HMGB1, a pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitis. Ocul Immunol Inflamm. 2011;19(3):180-185.
5. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17(4):359-365.
6. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1-5.
7. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol. 2005;26(7): 381-387.
8. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4): 331-342.
9. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006;17(3):189-201.
10. Watanabe T, Keino H, Sato Y, Kudo A, Kawakami H, Okada AA. High mobility group box protein-1 in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2009;50(5):2283-2290.
11. Arimura N, Ki-I Y, Hashiguchi T, Sakamoto T, Maruyama I. High-mobility group box 1 protein in endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2008;246(7):1053-1058.
12. Pachydaki SI, Tari SR, Lee SE, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res. 2006;82(5): 807-815.
13. Mollica L, De Marchis F, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007;14(4):431-441.
14. Girard JP. A direct inhibitor of HMGB1 cytokine. Chem Biol. 2007; 14(4):345-347.
15. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111(3):476-482.
16. Torkildsen GL, Cockrum P, Meier E, Hammonds WM, Silverstein B, Silverstein S. Evaluation of clinical efficacy and safety of tobramycin/ dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Curr Med Res Opin. 2011;27(1):171-178.
17. Dupont WD, Plummer WD. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11(2): 116-128.
18. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998;12(3):199-205.
19. van Rossum TG, Vulto AG, Hop WC, Schalm SW. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001;96(8):2432-2437.
20. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol. 2007;81:100-107.